An anthrax toxin variant with an improved activity in tumor targeting
Alexander N Wein1, Diane E Peters2,3, Zaheer Valivullah1
1Microbial Pathogenesis Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Scientific Reports
|November 21, 2015
Summary
Researchers engineered anthrax toxin components, protective antigen (PA) variants, to create highly specific cancer therapies. The new combination demonstrated potent anti-tumor activity with reduced toxicity, showing promise for targeted drug delivery.
Area of Science:
- Biochemistry
- Molecular Biology
- Biotechnology
Background:
- Anthrax lethal toxin (LT) comprises protective antigen (PA) and lethal factor (LF).
- PA binds cell receptors, forming oligomers for LF binding, crucial for toxicity.
- Previous PA variants (PA-U2-R200A, PA-L1-I210A) showed limited tumor targeting specificity.
Purpose of the Study:
- To develop PA variants with strictly complementation-dependent LF binding for enhanced tumor targeting.
- To identify improved PA variants that minimize residual LF-binding ability.
Main Methods:
- Screening a library of PA variants for amino acid substitutions in the LF-binding site.
- Evaluating cytotoxicity and LF-binding competence of new PA variants.
- Assessing the anti-tumor activity and toxicity of combined PA variants.
Main Results:
- Identified PA-I207R as a superior replacement for PA-L1-I210A.
- The new combination, PA-L1-I207R and PA-U2-R200A, exhibited enhanced specific tumor targeting.
- This combination demonstrated potent anti-tumor efficacy with significantly reduced toxicity compared to prior variants.
Conclusions:
- Engineered PA variants, PA-L1-I207R and PA-U2-R200A, offer improved tumor-specific delivery of anthrax lethal toxin components.
- This strategy enhances therapeutic potential by maximizing efficacy and minimizing off-target effects.
- Further investigation is warranted for clinical translation of these targeted toxin-based therapies.
Related Concept Videos
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
01:27Tumor Immunotherapy
2.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
01:12Bacterial Toxins
43
Bacterial toxins are sophisticated virulence factors that enable pathogenic bacteria to interact with, invade, and damage host tissues. These toxins fall broadly into two types: protein exotoxins, which are secreted into the environment and target specific host receptors, and lipopolysaccharide endotoxins, which are structural components of the bacterial outer membrane released primarily during bacterial lysis or membrane shedding. Exotoxins generally act more selectively, binding to cell...
43